New comprehensive review of aspirin chemoprevention of colorectal cancer.

I’m pleased to share the final product of a long-running project that I view as a great personal accomplishment. Our comprehensive review of aspirin chemoprevention entitled “Aspirin and colorectal cancer: the promise of precision chemoprevention” and co-authored with Dr. Yin Cao and Dr. Andrew T. Chan has been published as an Opinion article in Nature Reviews Cancer online and will appear in the March 2016 issue of the journal. To view the article please go to the Nature Reviews Cancer site or view it on PubMed (26868177).

ABSTRACT:

Aspirin (acetylsalicylic acid) has become one of the most commonly used drugs, given its role as an analgesic, antipyretic and agent for cardiovascular prophylaxis. Several decades of research have provided considerable evidence demonstrating its potential for the prevention of cancer, particularly colorectal cancer. Broader clinical recommendations for aspirin-based chemoprevention strategies have recently been established; however, given the known hazards of long-term aspirin use, larger-scale adoption of an aspirin chemoprevention strategy is likely to require improved identification of individuals for whom the protective benefits outweigh the harms. Such a precision medicine approach may emerge through further clarification of aspirin’s mechanism of action.